Correction: Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1- immunotherapy in colon cancer

Authors: Mark Awad, Mizuki Nishino, Mariano Severgnini, Biagio Ricciuti, Joao V Alessi, Gonzalo Recondo, Marissa Lawrence, Greg Jones, Tim Forshew, Christine Lydon, Michael Cheng

Source: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://jitc.bmj.com/content/9/3/e001643corr1.full; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/66aac74d6715476bb41128518795d259

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

Authors: Mark Awad, Mizuki Nishino, Mariano Severgnini, Biagio Ricciuti, Joao V Alessi, Gonzalo Recondo, Marissa Lawrence, Greg Jones, Tim Forshew, Christine Lydon, Michael Cheng

Source: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/e6145a4c40b5449aabb45da655be4ef6